ArticleCureus2025
Comparison of Stool Myeloperoxidase Levels and Their Association With Clinical Parameters in Children With Severe Acute Malnutrition, Children With Moderate Acute Malnutrition, and Healthy Children.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnvironmental enteropathy (EE) is a sub-clinical inflammatory condition of the intestine that contributes to malabsorption, growth failure, and impaired immunity in children from low-income countries. Stool myeloperoxidase (MPO) is a potential biomarker for assessing gut inflammation in malnourished children. The aim of the study was to estimate the MPO level in children with severe acute malnutrition (SAM), children with moderate acute malnutrition (MAM), and healthy children, and its association with clinical parameters.
methodsThis prospective observational study was conducted from September 2018 to May 2020 in a tertiary care teaching hospital in northern India. Inclusion criteria were children aged 2-60 months admitted/attending the outpatient department with WHO criteria of SAM and MAM, and age and sex matched healthy children. Variables recorded were age, sex, and socioeconomic status, and clinical data, including detailed history, anthropometry, systemic examination, and laboratory investigations. Human MPO enzyme-linked immunosorbent
resultsA total of 61 SAM, 25 MAM, and 15 healthy children were included. Median MPO levels were significantly higher in SAM (20,000 ng/g) compared to MAM (9,500 ng/g, p=0.004) and healthy children (8,250 ng/g, p<0.001). MPO levels were not significantly associated with diarrhea (p=0.82), edema (p=0.83), or stunting (p=0.86). ROC analysis identified a cut-off MPO level of 6,875 ng/g, yielding 98% sensitivity and 93% specificity for differentiating gut inflammation in SAM versus healthy children with an area under the curve (AUC) of 0.84 (95%CI, 0.77-0.93) (p=0.000).
conclusionSAM exhibited significantly elevated MPO levels without clinical correlation, indicating sub-clinical gut inflammation. MPO shows promise as a sensitive biomarker but requires validation in larger, longitudinal, and multi-biomarker studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.